Adrenocortical carcinoma (ACC) is an uncommon aggressive endocrine malignancy that is
nonetheless associated with significant mortality and morbidity rates because of endocrine …

DNA methylation profiling has been suggested a reliable technique to distinguish between
benign and malignant adrenocortical tumors, a process which with current diagnostic …

Etoposide, doxorubicin and cisplatin plus oral mitotane (EDP-M) comprise the reference
regimen in the management of patients with adrenocortical carcinoma (ACC). In this paper …

The pharmacological approach to adrenocortical carcinoma (ACC) is based on mitotane
with/without etoposide, doxorubicin, and cisplatin, according to the disease stage …

Background: Adrenocortical cancer (ACC) is a rare malignancy with a dismal prognosis. The
treatment includes mitotane and EDP chemotherapy (etoposide, doxorubicin, and cisplatin) …

Mitotane is the only approved drug for treating adrenocortical carcinoma (ACC). The
regimen added to mitotane is chemotherapy with etoposide, doxorubicin, and cisplatin. This …

Mitotane is the only drug approved for the treatment of adrenocortical carcinoma (ACC). The
regimen to be added to mitotane is a chemotherapy including etoposide, doxorubicin, and …

Purpose The management of patients with advanced/metastatic adrenocortical carcinoma
(ACC) is challenging, EDP-M (etoposide, doxorubicin, cisplatin combined with mitotane) is …

Background Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with a
poor prognosis. No efficacious treatment options are currently available for patients with …

Summary the evolving genomic landscape of ACC requires target validation in terms of
prognostic and predictive value within scientific consortia. Although the existing multiple …